First Amendment to Exclusive License AgreementExclusive License Agreement • November 9th, 2023 • Erasca, Inc. • Pharmaceutical preparations
This First Amendment to the Exclusive License Agreement (the “First Amendment”) effective as of August 7, 2023 (the “Amendment Effective Date”), is made by and between Erasca, Inc. (“Erasca”) and Novartis Pharma AG (“Novartis”) and amends the Exclusive License Agreement between the parties, dated December 9, 2022 (the “Agreement”).
